What are the lasting impacts of RSV, and how can you prevent your infant from getting the infection? Dr. Stephania Cormier is ...

Inhalon’s inhaled antibody therapy aims to address this need, the release said. Its RSV candidate is part of a more broad effort to develop therapies that deliver therapeutic antibodies directly to ...

Learn how analytical methodologies can be used to identify RSV pre- and post-fusion proteins for vaccine development.

New phase 2b/3 trial results with MSD's experimental respiratory syncytial virus (RSV) antibody clesrovimab have fired a shot across the bows of AstraZeneca and Sanofi, currently predicting ...

HealthDay News — For immunocompromised individuals, antibody response ... rise in preF immunoglobulin G (IgG) at 4 weeks. Overall, 139 participants reported RSV vaccination during the study ...

The vaccines, given in a single dose, stimulate the immune system to produce antibodies to protect against severe RSV infections and complications (e.g., pneumonia). The Centers for Disease ...

AstraZeneca and Sanofi have secured approval in the EU for Beyfortus, the first single-dose drug to protect newborns and infants from respiratory syncytial virus (RSV) infections. The antibody ...

Future Virology. 2014;9(8):753-767. CHF: Congestive heart failure; CLD: Chronic lung disease; F: Fusion; G: Glyco; GLA-SE: Glucopyranosyl lipid A-stable emulsion; GMT ...

There are currently no approved treatments for the underlying RSV infection," said John Whelan, president and chief executive officer of Inhalon Biopharma. "Inhalon’s inhaled antibody treatment ...

Respiratory syncytial virus (RSV) is a leading cause of respiratory infections in infants and a significant cause of respiratory infections in the elderly and adults with chronic obstructive ...